坎格瑞洛与糖蛋白IIb/IIIa抑制剂两种胃肠外抗血小板策略的缺血与出血风险评价:CHAMPION试验的探索性分析
基于3项CHAMPION三期试验的汇总患者水平数据探索性分析,比较经皮冠状动脉介入治疗(PCI)中坎格瑞洛单药与氯吡格雷联合糖蛋白IIb/IIIa抑制剂(GPI)的缺血与出血风险。倾向评分匹配后,两组主要疗效终点无显著差异,坎格瑞洛单药组TIMI定义的主要或次要出血显著更低。
要点
- 匹配队列中坎格瑞洛单药与氯吡格雷-GPI组主要疗效终点无显著差异(2.6% vs 3.3%;OR 0.79,95%CI 0.48-1.32)。
- 坎格瑞洛单药组TIMI定义主要或次要出血显著低于氯吡格雷-GPI组(0.7% vs 2.4%;OR 0.29,95%CI 0.13-0.68)。
- GUSTO定义严重/危及生命出血两组无显著差异(0.3% vs 0.7%;OR 0.43,95%CI 0.11-1.66)。
核心结论
- 基于3项CHAMPION三期试验的汇总分析,坎格瑞洛单药与氯吡格雷-GPI相比缺血风险相似、风险校正后出血风险更低。
研究设计与样本
- 3项三期CHAMPION试验(CHAMPION PCI、CHAMPION PLATFORM、CHAMPION PHOENIX)的汇总患者水平数据探索性分析。
- 纳入择期或非择期PCI患者:坎格瑞洛单药组10929例,氯吡格雷(或安慰剂)联合常规GPI组1211例。
- 排除需要补救或救援GPI治疗的患者;基于16项基线临床变量进行1:1倾向评分匹配,得到1021对匹配队列。
- 数据分析时间为2015年10月28日至2016年8月6日。
主要发现
- 共纳入12140例患者,男性8779例(72.3%),平均(SD)年龄63.2(11.3)岁。
- 氯吡格雷-GPI组男性比例更高(75.6% vs 71.9%)、更年轻(中位60岁[范围23-91] vs 64岁[范围26-95])、来自美国的比例更高(77.9% vs 40.0%)、急性冠脉综合征比例更高,但合并症负担更低、接受比伐卢定比例更低(8.8% vs 27.3%)。
- 匹配队列中主要疗效终点(48小时全因死亡、心肌梗死、缺血驱动血运重建或支架血栓复合终点)坎格瑞洛单药组与氯吡格雷-GPI组无显著差异(2.6% vs 3.3%;OR 0.79,95%CI 0.48-1.32)。
- GUSTO定义严重/危及生命出血坎格瑞洛单药组与氯吡格雷-GPI组无显著差异(0.3% vs 0.7%;OR 0.43,95%CI 0.11-1.66)。
- TIMI定义主要或次要出血坎格瑞洛单药组显著低于氯吡格雷-GPI组(0.7% vs 2.4%;OR 0.29,95%CI 0.13-0.68)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In the context of contemporary pharmacotherapy, optimal antiplatelet management with percutaneous coronary intervention (PCI) has not been well established. OBJECTIVE: To compare the ischemic and bleeding risks associated with glycoprotein IIb/IIIa inhibitors (GPIs) and a potent P2Y12 antagonist, cangrelor, in patients undergoing PCI. DESIGN, SETTING, AND PARTICIPANTS: An exploratory analysis of pooled patient-level data from the 3 phase 3 Cangrelor vs Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PCI, CHAMPION PLATFORM, and CHAMPION PHOENIX) trials of patients undergoing elective or nonelective PCI. The participants included 10 929 patients assigned to cangrelor but not receiving GPIs (cangrelor alone) and 1211 patients assigned to clopidogrel (or placebo) and receiving routine GPIs (clopidogrel-GPI). Patients requiring bailout or rescue GPI therapy were excluded. To account for risk imbalances, 1:1 propensity score matching based on 16 baseline clinical variables yielded 1021 unique matched pairs. The present study's data analysis was conducted from October 28, 2015, to August 6, 2016. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was the composite of all-cause mortality, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours. Safety was assessed by 3 validated bleeding scales (Global Use of Strategies to Open Occluded Coronary Arteries [GUSTO], Thrombolysis in Myocardial Infarction [TIMI], and Acute Catheterization and Urgent Intervention Triage) and requirement for blood transfusions. RESULTS: Of the 12 140 patients included in the analysis, 8779 were men (72.3%), and the mean (SD) age was 63.2 (11.3) years. Patients in the clopidogrel-GPI group were more likely to be male (75.6% vs 71.9%), younger (median, 60 [range, 23-91] years vs 64 [range, 26-95] years), enrolled from the United States (77.9% vs 40.0%), and present with an acute coronary syndrome, but they had lower comorbid disease burden and were less likely to receive bivalirudin (8.8% vs 27.3%). In the matched cohorts, the rates of the primary efficacy end point were not significantly different between the cangrelor alone and clopidogrel-GPI groups (2.6% vs 3.3%; odds ratio [OR], 0.79; 95% CI, 0.48-1.32). There was a nonsignificant trend toward lower rates of GUSTO-defined severe/life-threatening bleeding with cangrelor alone compared with clopidogrel-GPI (0.3% vs 0.7%; OR, 0.43; 95% CI, 0.11-1.66). Rates of TIMI-defined major or minor bleeding were significantly lower in patients treated with cangrelor alone (0.7% vs 2.4%; OR, 0.29; 95% CI, 0.13-0.68). CONCLUSIONS AND RELEVANCE: Based on a pooled analysis from the 3 phase 3 CHAMPION trials, cangrelor alone was associated with similar ischemic risk and lower risk-adjusted bleeding risk compared with clopidogrel-GPIs. TRIAL REGISTRATION: clinicaltrials.gov Identifiers: NCT00305162, NCT00385138, and NCT01156571.
引用
- Vaduganathan M, Harrington RA, Stone GW, et al. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. JAMA Cardiol. 2017. PMID: 27902833. doi:10.1001/jamacardio.2016.4556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。